Purpose: OnabotulinumtoxinA is a well described treatment of neurogenic overactive bladder. While motor effects on the detrusor muscle have been extensively studied, the sensory effects have not. The aim of this study was to evaluate the impact of intradetrusor onabotulinumtoxinA injection on brain activity in female patients with multiple sclerosis and neurogenic overactive bladder. Materials and Methods: We prospectively studied 12 women with stable multiple sclerosis and neurogenic overactive bladder using concurrent functional magnetic resonance imaging and urodynamic studies prior to and 6 to 10 weeks following onabotulinumtoxinA injection. Individual functional magnetic resonance imaging activation maps at the time of strong urgency were averaged before and after onabotulinumtoxinA injection where areas of significant activation were identified. Results: After onabotulinumtoxinA injection functional magnetic resonance imaging activation increased in the right cingulate body (p ¼ 0.0012), the left posterior cingulate (p ¼ 0.02), the left anterior cingulate (p ¼ 0.0015), the right prefrontal cortex (p ¼ 0.0015), the insula (p ¼ 0.0138) and the pons micturition center (p ¼ 0.05). Sparse areas showed decreased activity, including the left cerebellum (p ¼ 0.001), the left fusiform gyrus (p ¼ 0.065) and the bilateral lentiform nucleus (p ¼ 0.026). Conclusions: Intradetrusor injection of onabotulinumtoxinA appeared to increase the activity of most brain regions known to be involved in the sensation and process of urinary urgency in female patients with multiple sclerosis and neurogenic overactive bladder. To our knowledge this is the first study of its kind to evaluate the possible effects of onabotulinumtoxinA at the human brain level where sensory awareness is located. This activation pattern may be used to Accepted for publication July 26, 2018. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
MULTIPLE sclerosis is a chronic, multifocal demyelinating disease that affects the central nervous system, mainly the brain. Urinary frequency, urgency or UUI, referred to as NOAB, are the most common symptoms, occurring in 37% to 99% of patients with MS. 1 Urgency and UUI negatively impact health related quality of life. 2 OnabotA blocks the release of acetylcholine at the neuromuscular junction and leads to temporary chemodenervation of the bladder. The motor effects of OnabotA on the bladder have been extensively studied, 3 which led to its approval by the United States FDA (Food and Drug Administration) in August 2011 to treat NOAB in patients with MS. 4e6 Despite significant animal and human research on the motor effects of OnabotA, its sensory effects specifically correlating with brain regions for the perception and/or localization of bladder fullness, urgency and frequency in humans is not well understood. 7 With advances in neuroimaging fMRI has been used to evaluate brain responses to cold sensation 8 and urinary urgency, 9 elucidating the supraspinal areas involved in the perception of bladder sensation. To our knowledge whether intradetrusor OnabotA effects in humans extend to the brain level remains to be elucidated. Potentially fMRI represents an unprecedented modality to determine the effects of OnabotA on the regions of the brain which regulate micturition.
The aim of this study was to evaluate the effects of intradetrusor OnabotA on brain activity in female patients with MS and NOAB using concurrent fMRI and UDS in a priori ROIs at the time of strong desire to void (full urge). We hypothesized that intradetrusor OnabotA in our cohort would modulate (decrease) activity in ROIs as characterized by BOLD activation patterns on fMRI.
METHOD
We performed an observational prospective study prior to patient selection, which was approved by our Institutional Review Board (IRB No. Pro00005508). The trial was registered at ClinicalTrials.gov (NCT03033355). The complete, detailed study protocol was previously published. 10 
Patient Selection and Recruitment
Study inclusion criteria were adult female patients with MS that had been clinically stable for 3 months or more before screening, an EDSS (Expanded Disability Status Score) of 6.5 or less with urinary frequency or urgency, disease refractory to behavioral therapies and oral pharmacological management of NOAB, and an interest in OnabotA intradetrusor injection. Men were excluded from study to avoid confounding by prostate and bladder outlet pathology. Other exclusion criteria were severe debilitating disease, pregnancy or the intent to become pregnant, nursing, MRI contraindications, a history of augmentation cystoplasty and the presence of other neurological diseases. Patients were screened at and recruited from our neurourology clinic.
Evaluation
Each patient underwent a detailed history and physical examination, and completed a baseline clinic UDS. Questionnaires and assessments were obtained at baseline and 6 to 10 weeks after OnabotA injection, including the UDI-6, the IIQ-7, the MRI Safety Screening Questionnaire and the HAM-A (Hamilton Anxiety Rating Scale), PVR volume and urinalysis. Patients were seen for followup in the clinic 2 and 6 weeks following OnabotA treatment for symptom evaluation, urinalysis and PVR volume measurement. If there were clinical signs of increased PVR volume or urinary retention, CIC was initiated.
Intradetrusor OnabotulinumtoxinA Injection
OnabotA was injected in 2 of the patients who voided spontaneously (100 U) and in patients dependent on CIC (200 U) cystoscopically throughout the bladder, including the trigone.
Simultaneous Urodynamic Testing and Functional Magnetic Resonance Imaging
We used our previously established fMRI/UDS platform in healthy females and patients with MS. 11, 12 Double lumen 7Fr MRI compatible catheters were placed in the bladder and the rectum. An Ingenia 3.0 Tesla full body MRI device (Philips, Andover, Massachusetts) with a standard 12 channel head coil was used. Before imaging the patient received instructions to communicate using right hand signals representing a strong desire to void (full urge), voiding and voiding completed. To avoid auditory or other extensive brain stimulation not related to the voiding process simple signs were shown to the patient when bladder filling began and when filling stopped. Also, to maintain a low noise-to-signal ratio all stimulators, including any extra visual stimuli and the urodynamic machine, were removed from the MRI room.
Total scan time was limited to 45 minutes. For anatomical reference a high resolution, 3-dimensional brain scan was acquired (T1-weighted, 0.7 mm isotropic 3-dimensional resolution). Echoplanar imaging (repetition time 3 seconds, in-plane resolution 3.4 mm and slice thickness 4 mm) was performed during 2 functional tasks to record the BOLD signal.
The patient used the right hand to perform instruction signals (tasks) without voiding. The signals were scanned separately to obtain a baseline of fMRI activation caused by signaling alone. Subsequently urodynamic testing and the filling task were initiated simultaneously. The bladder was filled at 50 ml per minute with room temperature, sterile normal saline solution until the participant indicated a strong desire to void. Filling was stopped and the participant was asked to hold urine for 30 seconds. Then the patient was allowed to void or attempt to void into absorbent pads on the scanner table. The bladder was aspirated if patient was unable to void. To create a block design fMRI task this sequence was repeated up to 4 times. The final catheterizable PVR volume was recorded. This procedure was performed before treatment and 6 to 10 weeks after OnabotA injection.
Data Analysis and Statistics
The BOLD fMRI images were analyzed as described previously.
11,12 A healthy female cohort described in a previous report served as HCs.
12 AFNI (Analysis of Functional NeuroImages) software (https://afni.nimh.nih.gov/afni/) was used for fMRI BOLD analysis.
Structural and functional images were registered to each other. The echoplanar fMRIs were motion corrected. Patients with large motion (greater than 4.5 mm) were excluded from analysis. Voxel activation was identified at the time of the strong desire to void (full urge) and BOLD fMRI activation maps were calculated using standard analysis with a generalized linear model. Group analysis was performed by transforming data into the Talairach space and significantly activated voxels were identified with the Student t-test.
We compared participants with MS by comparing baseline scans to scans after OnabotA treatment. In addition, patients with MS were compared to the HC cohort before and after OnabotA injection. We determined that 12 subjects would provide 80% power at the single voxel level for typical activation, accounting for intrasubject and intersubject variability, based on prior fMRI power calculation data. 13 In most trials in which fMRI was applied to evaluate lower urinary tract function, specifically the 2 most recent and similar trials, power was set at 12 patients. 14, 15 Based on prior functional neuroimaging studies evaluating areas related to bladder fullness in women with nonneurogenic overactive bladder 16 our analysis focused on certain ROIs, including the cingulate cortex, the insula, the prefrontal cortex, the pons, the cerebellum, the thalamus and the amygdala.
RESULTS
A total of 12 female patients with MS, a mean age of 43.9 years (range 38 to 71) and a mean MS history of 14.9 years (range 2 to 38) completed the study. Ten patients were ambulatory and 2 were wheelchair bound. All patients had lesions of varying sizes which were located in the cerebrum. Table 1 summarizes patient demographics and evaluations at baseline and following intradetrusor injection of OnabotA. Ten patients received 200 U OnabotA and 2 of the 4 who voided spontaneously received 100 U. Our cohort received a mean of 2.08 repeat OnabotA injections (range 0 to 7). At baseline 8 patients performed CIC and 3 of the 4 who voided spontaneously needed to initiate self-catheterization after treatment, leaving 11 on CIC after OnabotA injection. In all patients the total IIQ-7 and UDI-6 scores improved, specifically questions 1 and 2, which address urinary frequency and UUI, respectively. Statistically significant increases in BOLD activation signals after OnabotA were observed in the right and the left cingulate, the right prefrontal cortex, the insula and the pons micturition center. Areas showing decreased activity were sparse, including the left cerebellum (p ¼ 0.001), the left fusiform gyrus (p ¼ 0.065) and the bilateral lentiform nucleus (p ¼ 0.026, table 2). Figure 1 shows the subtraction of post-pre OnabotA BOLD patterns at ROI overall. Figure 2 demonstrates BOLD signal patterns in the amygdala and the parahippocampal gyrus at baseline and the decrease after OnabotA injection. Following OnabotA injection the overall BOLD patterns in the brain were less different than the HC cohort pattern with most changes evident in the frontal lobes ( fig. 3 ).
DISCUSSION
Studies suggest that OnabotA in the bladder has several mechanisms of action besides an inhibitory effect on neurotransmitter release from parasympathetic nerve terminals on the detrusor muscle. 7 In humans with overactive bladder the activation of specific receptors involved in afferent signaling pathways, such as P2X 2 and P2X 3 , are reduced by OnabotA, suggesting that OnabotA works by inhibiting sensory and motor aspects of detrusor function. 17 Moreover, some studies support the idea of a potential role of sensory purinergic pathways in the development of bladder overactivity and suggest that OnabotA may reduce purinergic transmission. 18 Prior neuroimaging studies suggested that the specific brain regions involved with processing the sensation of bladder fullness and urgency in nonneurogenic overactive bladder cases are the cingulate, insular and frontal (prefrontal) cortices, which show increased activation patterns as bladder volume increases. 19 These areas appear to change following nonneurogenic OAB therapeutic interventions such as biofeedback, 20 anticholinergic medications 21 and sacral neuromodulation, 14 displaying brain neuroplasticity.
To our knowledge our trial is the first of its kind to evaluate the possible effects of intradetrusor injection of OnabotA at the level of the human brain where the perception and processing of fullness is located. Our results are complementary and similar in part to the current literature and yet different in some aspects. We found that OnabotA injection in the bladder appeared to have distinct effects on the activation pattern of brain regions associated with the sensation of bladder filling, urgency and micturition. For the most part our results showed increased activity after OnabotA injection in the cingulate and prefrontal cortices, the insula, the pons and the thalamus. This is in contrast to findings in some studies in which other OAB interventions were applied, including biofeedback, 20 anticholinergic medications 21 and sacral neuromodulation.
14,15
These differences could have been due to multiple factors. Our cohort consisted of patients with MS who had refractory neurogenic OAB, which is inherently unlike and unique by definition compared to idiopathic OAB in patients in the former studies. 14, 15, 20, 21 Griffiths et al found that older, community dwelling women with urge urinary incontinence who did not respond to biofeedback assisted, pelvic floor physical therapy showed a distinct neuroimaging brain activation pattern with the medial prefrontal cortex deactivated at baseline. 19, 20 In our cohort of patients with MS who had NOAB at baseline and prior to OnabotA injection we observed similarly decreased BOLD activation, especially in the left superior frontal gyrus, which could possibly have been due to the greater severity of NOAB symptoms experienced by our patients (fig. 3) .
Our cases appeared to be a different cohort altogether since they were already refractory to pelvic floor physical therapy and oral medications. Furthermore, due to the diffuse, multifocal involvement of brain plaque in patients with MS symptom severity and the impact on quality of life may vary from patient to patient. 22 ,23 MS lesions also affect functional connectivity between ROIs at baseline and after NOAB management, making it interesting and yet more challenging to interpret these results. Despite this, after OnabotA injection the overall BOLD signal patterns in the brain became less different between the MS group and the HCs at the time of full urge ( fig. 3 ). Another finding in our cohort is that the entire micturition cycle, including the voiding phase, changed after intradetrusor injection of OnabotA. Patients showed increased maximum cystometric capacity and PVR, requiring de novo CIC in 3 of the 4 who had voided spontaneously at baseline. 24, 25 Such a strong impact on the voiding phase, specifically a negative effect, is in contrast to other OAB therapies. We believe that this negative effect on the voiding phase of the micturition cycle could possibly have an effect on the brain, causing an increased BOLD signal activation pattern to enable voiding or attempted voiding.
An additional, thought provoking argument for our findings is that we evaluated brain activation patterns after OnabotA injection at much higher bladder volume (larger maximum cystometric capacity). The BOLD activation patterns from the visceral organs (bowel and bladder 19,26e28 ) have a direct, distention related relationship with capacity. Increased BOLD signals are seen at higher bladder and bowel volumes. The increased signals in our cohort after OnabotA treatment could potentially have been due to the fact that full urge was registered at a larger bladder volume and the data analysis was performed at that point.
Finally, we would like to discuss our intriguing findings in the amygdala and the parahippocampal region. The amygdala, which is part of the limbic system, is responsible for processing negative and fearful sensations such as urgency and urge urinary incontinence. 27 In a previous study the amygdala/ parahippocampal region appeared to demonstrate decreased BOLD signal activation after successful chronic neuromodulation treatment of UUI. 29 This is similar to our results, in which BOLD activation decreased following successful treatment of NOAB with OnabotA injection.
Further studies are undoubtedly needed in a larger population of patients with OAB and NOAB who undergo OnabotA injection to increase our understanding of the brain and the potentially sensory effects of intradetrusor OnabotA.
CONCLUSIONS
To our knowledge this is the first study of its kind to evaluate the possible effects of intradetrusor injection of OnabotA at the human brain level where sensory awareness is located. BOLD activation patterns appeared to increase in female patients with MS as well as NOAB in most of the brain regions involved in the sensation and processing of urinary urgency, possibly because data analysis was performed at higher bladder volumes. These effects were reversed in the amygdala and the parahippocampal region, where fear and anxiety (possibly due to urgency and UUI) are processed. This BOLD signal activation/deactivation pattern may be used to phenotype patients further to optimize therapy or determine the sensory effects of OnabotA beyond the bladder.
